User profiles for Alfonso E. Bello
 | Alfonso E. Bello, MD, MHSClinical Associate Professor of Medicine, University of Illinois Verified email at ibji.com Cited by 2772 |
Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study
PURPOSE: To evaluate the efficacy and upper gastrointestinal (UGI) safety of celecoxib,
compared with nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs), among patients with …
compared with nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs), among patients with …
Cyclooxygenase-2–specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients
…, JA Puma, D Normandin, AE Bello… - American journal of …, 2001 - journals.lww.com
Background Arthritis and hypertension are common comorbid conditions affecting elderly
adults. Use of nonsteroidal anti-inflammatory drugs in patients treated with antihypertensive …
adults. Use of nonsteroidal anti-inflammatory drugs in patients treated with antihypertensive …
Effects of celecoxib and rofecoxib on blood pressure and edema in patients≥ 65 years of age with systemic hypertension and osteoarthritis
Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs), including the cyclooxygenase-2
(COX-2) specific inhibitors, with antihypertensive medication is common practice for …
(COX-2) specific inhibitors, with antihypertensive medication is common practice for …
Collagen hydrolysate for the treatment of osteoarthritis and other joint disorders: a review of the literature
AE Bello, S Oesser - Current medical research and opinion, 2006 - Taylor & Francis
Background: There is a need for an effective treatment for the millions of people in the United
States with osteoarthritis (OA), a degenerative joint disease. The demand for treatments, …
States with osteoarthritis (OA), a degenerative joint disease. The demand for treatments, …
Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis
AE Bello, EL Perkins, R Jay… - … : research and reviews, 2017 - Taylor & Francis
Methotrexate (MTX) remains the cornerstone therapy for patients with rheumatoid arthritis (RA),
with well-established safety and efficacy profiles and support in international guidelines. …
with well-established safety and efficacy profiles and support in international guidelines. …
Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers
L Laine, AJ Kivitz, AE Bello, AY Grahn… - Official journal of the …, 2012 - journals.lww.com
… Bello, and Michael H. Schiff; analysis/interpretation of data, critical review of the manuscript,
… Alfonso E. Bello is a consultant for Horizon Pharma and Pfizer; is a speaker for Abbott and …
… Alfonso E. Bello is a consultant for Horizon Pharma and Pfizer; is a speaker for Abbott and …
Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen
EF Ekman, JS Gimbel, AE Bello, MD Smith… - The Journal of …, 2014 - jrheum.org
Objective. Two studies evaluated efficacy and safety of tanezumab versus naproxen for
treatment of knee or hip osteoarthritis (OA). Methods. Randomized controlled studies [ …
treatment of knee or hip osteoarthritis (OA). Methods. Randomized controlled studies [ …
Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip
L Tive, AE Bello, D Radin, TJ Schnitzer… - Journal of pain …, 2019 - Taylor & Francis
Purpose A pooled analysis was conducted to evaluate tanezumab efficacy and safety in
patients with osteoarthritis (OA), including subgroup analyses of at-risk patients with diabetes, …
patients with osteoarthritis (OA), including subgroup analyses of at-risk patients with diabetes, …
[HTML][HTML] Cardiovascular risk with non-steroidal anti-inflammatory drugs: clinical implications
AE Bello, RJ Holt - Drug safety, 2014 - Springer
In February 2014, the US Food and Drug Administration (FDA) convened an advisory
committee meeting to discuss the accumulated data relating to the cardiovascular risk of non-…
committee meeting to discuss the accumulated data relating to the cardiovascular risk of non-…
[HTML][HTML] Characteristics, comorbidities, and potential consequences of uncontrolled gout: an insurance-claims database study
…, L Padnick-Silver, RJ Holt, AE Bello - Rheumatology and …, 2021 - Springer
Introduction Gout is a common, progressive, systemic inflammatory arthritis caused by
hyperuricemia. Current guidelines recommend that serum uric acid (sUA) levels be maintained …
hyperuricemia. Current guidelines recommend that serum uric acid (sUA) levels be maintained …